Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma
- 1 March 2017
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 484 (2) , 378-384
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of China (81372259)
This publication has 25 references indexed in Scilit:
- Evaluating cost benefits of combination therapies for advanced melanomaDrugs in Context, 2016
- Novel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaJournal of Clinical Medicine Research, 2016
- Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and ImmunotherapyBioMed Research International, 2015
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4Clinical Cancer Research, 2015
- Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced MelanomaJournal of Managed Care Pharmacy, 2014
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersNature, 2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established TumorsCancer Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010